James Mulay Sells 19,112 Shares of CG Oncology (NASDAQ:CGON) Stock

Key Points

• CG Oncology Director James Mulay sold 19,112 shares of stock for $745,559.12 on September 18 at an average price of $39.01.
• CG Oncology's stock is currently trading at $36.70, down 0.5%, with a 1-year low of $14.80 and a high of $40.47.
• Analysts have set a consensus target price of $56.00 for CG Oncology, with ratings ranging from "Strong Buy" to "Sell" based on various equity research reports.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 19,112 shares of the business's stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $39.01, for a total value of $745,559.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

James Mulay also recently made the following trade(s):

• On Friday, September 19th, James Mulay sold 3,574 shares of CG Oncology stock. The shares were sold at an average price of $38.99, for a total value of $139,350.26.
• On Friday, September 5th, James Mulay sold 27,015 shares of CG Oncology stock. The shares were sold at an average price of $31.53, for a total value of $851,782.95.

CG Oncology Stock Up 0.4%

CG Oncology stock traded up $0.14 during midday trading on Monday, reaching $37.04. The stock had a trading volume of 725,022 shares, compared to its average volume of 1,159,940. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $40.47. The firm's 50-day moving average price is $28.44 and its 200 day moving average price is $26.01. The firm has a market capitalization of $2.82 billion, a PE ratio of -20.93 and a beta of 0.87.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. Equities research analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current year.

Institutional Trading of CG Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Winthrop Capital Management LLC purchased a new stake in CG Oncology in the second quarter worth approximately $38,000. GF Fund Management CO. LTD. purchased a new stake in CG Oncology in the fourth quarter worth approximately $41,000. CWM LLC boosted its stake in CG Oncology by 3,957.7% in the first quarter. CWM LLC now owns 2,110 shares of the company's stock worth $52,000 after buying an additional 2,058 shares in the last quarter. GAMMA Investing LLC boosted its stake in CG Oncology by 1,051.0% in the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after buying an additional 2,102 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in CG Oncology by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock valued at $77,000 after purchasing an additional 398 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. The Goldman Sachs Group raised CG Oncology to a "strong-buy" rating and set a $40.00 target price for the company in a report on Thursday, July 10th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of CG Oncology in a report on Monday, September 15th. Jones Trading assumed coverage on CG Oncology in a report on Monday, September 8th. They set a "buy" rating and a $50.00 target price for the company. Morgan Stanley lifted their target price on CG Oncology from $56.00 to $79.00 and gave the company an "overweight" rating in a report on Wednesday, September 17th. Finally, Wall Street Zen lowered CG Oncology from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $56.00.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.